Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

AIDS

Volumn 14, Issue 18, 2000, Pages 2895-2902

  Den Brinker, Marieke ^a   Wit, Ferdinand W N M ^a   Wertheim van Dillen, Pauline M E ^a   Jurriaans, Suzanne ^a   Weel, Jan ^a   Van Leeuwen, Remko ^a   Pakker, Nadine G ^a   Reiss, Peter ^a   Danner, Sven A ^a   Jan Weverling, Gerrit ^a   Lange, Joep M A ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Hepatitis B virus; Hepatitis C virus; Hepatotoxicity; Highly active antiretroviral therapy; HIV 1; Liver enzyme elevation

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; DIDANOSINE; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; HEPATITIS C ANTIBODY; INDINAVIR; LAMIVUDINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SUPERINFECTION;

ADULT; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ASPARTATE AMINOTRANSFERASES; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C; HEPATITIS, TOXIC; HIV INFECTIONS; HIV-1; HUMANS; LIVER FUNCTION TESTS; MALE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0034523342     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200012220-00011     Document Type: Article

References (28)

1. Treatment of HIV infection. Tolerability of commonly used antiretroviral agents
2. Restoration of immunity to chronic hepatitis B Infection in HIV-infected patient on protease inhibitor
3. Severe hepatitis in three AIDS patients treated with indinavir
4. Is the combination of hepatitis and indinavir potentially dangerous?
5. Effects of HAART on natural history of AIDS-related opportunistic disorders
6. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy
7. Severe hepatic cytolysis: Incidence and risk factors in patients treated by antiretroviral combinations Aquitaine Cohort, France, 1996-1998
8. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
9. Prevalence of HBV, HDV and HCV hepatitis markers in HIV-positive patients
10. Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons
11. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
12. Hepatitis B virus infection
13. Hepatitis C
14. Persistant hepatitis C virus RNA replication in haemophiliacs: Role of coinfection with human immunodeficiency virus
15. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection
16. Recovery of the immune system with antiretroviral therapy. The end of opportunism?
17. Cytomegalovirus disease in HIV-1-infected patients treated with protease inhibitors
18. Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients
19. Relationship between expression of hepatitis B virus antigens in isolated hepatocytes and autologous lymphocyte cytotoxicity in patients with chronic hepatitis B virus injection
20. Immunoregulatory T-cell function in acute and chronic liver disease
21. Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus
22. The influence of HTLV-III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers
23. Resolution of chronic hepatilis B after ritonavir treatment in an HIV-infected patient
24. Effects of short-term corticosteroid therapy in patients with chronic Non-A Non-B hepatitis (NANB)
25. Rapidly progressive Non-A, Non-B hepatitis in patients with human immunodeficiency virus infection
26. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway